New pill tested for Tough-to-Treat lung cancer
NCT ID NCT05363280
Summary
This study is testing a new oral medication called AL8326 for people with recurrent small cell lung cancer who need a second or later line of treatment. The main goals are to find the safest and most effective dose and to see if the drug helps shrink tumors. The trial will involve about 36 patients initially, with a possible expansion to more patients later.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario Ramón Y Cajal
Madrid, Spain
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Siteman Cancer Center, Washington University
St Louis, Missouri, 63130, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.